The Directors of MGC Pharmaceuticals Ltd (the “Company”) request that the Company’s securities be placed in a voluntary trading halt immediately in accordance with ASX Listing Rule 17.1, pending the release of an announcement by the Company regarding the Good Manufacturing Practice (GMP) certification approval process being sought by the Company to commence production at its European Medicinal Cannabis Laboratory and Extraction Facility of pharmaceutical grade medicinal cannabis products.
